TY - JOUR
T1 - Early Detection of Cardiotoxicity Using [64Cu]Cu-NODAGA-E[(cRGDyK)]2 PET Imaging in a Rat Model of Doxorubicin-Induced Heart Failure
AU - Hoeeg, Cecilie
AU - Follin, Bjarke
AU - Grandjean, Constance Eline
AU - Ripa, Rasmus Sejersten
AU - Ekblond, Annette
AU - Kastrup, Jens
AU - Binderup, Tina
AU - Kjaer, Andreas
PY - 2024/8/5
Y1 - 2024/8/5
N2 - Doxorubicin (DOX) is a common and highly effective chemotherapeutic. However, its use is limited by cardiotoxic effects and the lack of methods to detect these at early time points. In the present study, we evaluated if [64Cu]Cu-NODAGA-E[(cRGDyK)]2 positron emission tomography-computed tomography ([64Cu]Cu-RGD PET/CT) could detect cardiotoxicity in a rat model of DOX-induced heart failure. Male Lewis rats were divided into two groups and treated with either a cumulative dose of 15 mg/kg of DOX or left untreated. Cardiac anatomy and function were assessed using magnetic resonance imaging at baseline and in week 8. [64Cu]Cu-RGD PET/CT scans were performed in week 4. DOX treatment led to a decline in pump function as well as an increase in cardiac and thymic uptake of [64Cu]Cu-RGD. In addition, DOX altered cardiac gene expression, led to infiltration of immune cells, reduced endothelial content, and increased interstitial fibrosis. Furthermore, concentrations of inflammatory plasma proteins were increased in the DOX group. In conclusion, DOX treatment resulted in the development of cardiotoxicity and heart failure, which could be detected using [64Cu]Cu-RGD PET/CT at early time points. [64Cu]Cu-RGD uptake in the myocardial septum and thymus predicted a low left ventricular ejection fraction in week 8.
AB - Doxorubicin (DOX) is a common and highly effective chemotherapeutic. However, its use is limited by cardiotoxic effects and the lack of methods to detect these at early time points. In the present study, we evaluated if [64Cu]Cu-NODAGA-E[(cRGDyK)]2 positron emission tomography-computed tomography ([64Cu]Cu-RGD PET/CT) could detect cardiotoxicity in a rat model of DOX-induced heart failure. Male Lewis rats were divided into two groups and treated with either a cumulative dose of 15 mg/kg of DOX or left untreated. Cardiac anatomy and function were assessed using magnetic resonance imaging at baseline and in week 8. [64Cu]Cu-RGD PET/CT scans were performed in week 4. DOX treatment led to a decline in pump function as well as an increase in cardiac and thymic uptake of [64Cu]Cu-RGD. In addition, DOX altered cardiac gene expression, led to infiltration of immune cells, reduced endothelial content, and increased interstitial fibrosis. Furthermore, concentrations of inflammatory plasma proteins were increased in the DOX group. In conclusion, DOX treatment resulted in the development of cardiotoxicity and heart failure, which could be detected using [64Cu]Cu-RGD PET/CT at early time points. [64Cu]Cu-RGD uptake in the myocardial septum and thymus predicted a low left ventricular ejection fraction in week 8.
KW - Acetates/chemistry
KW - Animals
KW - Cardiotoxicity/etiology
KW - Copper Radioisotopes
KW - Disease Models, Animal
KW - Doxorubicin/adverse effects
KW - Heart Failure/chemically induced
KW - Heart/drug effects
KW - Heterocyclic Compounds, 1-Ring
KW - Magnetic Resonance Imaging/methods
KW - Male
KW - Positron Emission Tomography Computed Tomography/methods
KW - Positron-Emission Tomography/methods
KW - Radiopharmaceuticals
KW - Rats
KW - Rats, Inbred Lew
KW - heart failure
KW - PET imaging
KW - cobber-64
KW - cardiotoxicity
KW - inflammation
UR - http://www.scopus.com/inward/record.url?scp=85197584599&partnerID=8YFLogxK
U2 - 10.1021/acs.molpharmaceut.4c00272
DO - 10.1021/acs.molpharmaceut.4c00272
M3 - Journal article
C2 - 38936409
SN - 1543-8384
VL - 21
SP - 3909
EP - 3920
JO - Molecular Pharmaceutics
JF - Molecular Pharmaceutics
IS - 8
ER -